Factors Associated With Neurological Manifestations in Patients With COVID-19 Neurological Manifestations of COVID-19.
International Clinical Neuroscience Journal,
Vol. 9 (2022),
10 January 2022
,
Page e27
Abstract
Background: The coronavirus disease 2019 (COVID-19) is the most terrible pandemic of a respiratory disease that we had in the past century. Most existing studies explore different manifestations in COVID-19. Few recent studies have described neurological manifestations of patients with COVID-19 but their associations with age, laboratory findings, and mortality rates have not been explored well.
Methods: This case-control study includes 263 patients with COVID-19 without neurological symptoms (control group) and all patients with COVID-19 with the central nervous system symptoms (n = 460, case group) hospitalized between February 2020 and April 2020. Data on demographic factors, medical history, symptoms, and laboratory tests, all are extracted from medical records.
Results: Out of 723 patients with confirmed SARS-CoV-2 infection, 460 (63.6%) were identified to have at least one neurological manifestation. The mean ages of patients with and without neurological manifestation were 60.6 ± 18.0 and 60.8 ± 15.7 years, respectively. The most common symptoms were myalgia (41%), headache (20.3%), and loss of consciousness (LOC) (16.5%). Women were more likely to develop a neurological manifestation (P = 0.001). Moreover, smoking history was significantly more in patients with neurological manifestations (P = 0.03). Also, we compared two groups in terms of tracheal intubation. The need for tracheal intubation was 19% and 12% in patients with and without neurological manifestations, respectively. Furthermore, the prevalence of intensive care unit (ICU) admission was 28% and 24% in patients with COVID-19, with and without neurological manifestations, respectively. Some of the neurological manifestations such as LOC, limbs weakness, and seizure might need more ICU admission and tracheal intubation. The frequency of comorbidities and the laboratory test results were almost similar between the two groups.
Conclusion: Myalgia, headache, and LOC were the most common neurological manifestations and their distributions varied depending on age. Only a few neurological manifestations were related to mortality and morbidity rates, while some of them occurred in mild cases.
- Neurology
- COVID-19
- SARS-CoV-2
- Neurological manifestation
How to Cite
References
Wong J, Goh QY, Tan Z, Lie SA, Tay YC, Ng SY, et al. Preparing for a COVID-19 pandemic: a review of operating room outbreak response measures in a large tertiary hospital in Singapore. Can J Anaesth. 2020;67(6):732-45. doi: 10.1007/ s12630-020-01620-9.
Lahiri D, Mondal R, Deb S, Bandyopadhyay D, Shome G, Sarkar S, et al. Neuroinvasive potential of a primary respiratory pathogen SARS- CoV2: summarizing the evidences. Diabetes Metab Syndr. 2020;14(5):1053-60. doi: 10.1016/j. dsx.2020.06.062.
Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552-5. doi: 10.1002/jmv.25728.
Sepehrinezhad A, Shahbazi A, Sahab Negah Negah S. COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review. J Neurovirol. 2020;26(3):324-9. doi: 10.1007/s13365-020- 00851-2 .
Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci. 2020;413:116832. doi: 10.1016/j.jns.2020.116832.
Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv [Preprint]. February 25, 2020. Available from: https:// www.medrxiv.org/content/10.1101/2020.02.22.20026500v1.
Stefanou MI, Palaiodimou L, Bakola E, Smyrnis N, Papadopoulou M, Paraskevas GP, et al. Neurological manifestations of long-COVID syndrome: a narrative review. Ther Adv Chronic Dis. 2022;13:20406223221076890. doi: 10.1177/20406223221076890.
Baig AM. Counting the neurological cost of COVID-19. Nat Rev Neurol. 2022;18(1):5-6. doi: 10.1038/s41582-021- 00593-7.
Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268-70. doi: 10.1056/NEJMc2008597.
Bhola S, Trisal J, Thakur V, Kaur P, Kulshrestha S, Bhatia SK, et al. Neurological toll of COVID-19. Neurol Sci. 2022;43(4):2171- 86. doi: 10.1007/s10072-022-05875-6.
Premraj L, Kannapadi NV, Briggs J, Seal SM, Battaglini D, Fanning J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci. 2022;434:120162. doi: 10.1016/j.jns.2022.120162.
Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: a literature review. J Clin Neurosci. 2020;77:8-12. doi: 10.1016/j.jocn.2020.05.017.
Niazkar HR, Zibaee B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: a review article. Neurol Sci. 2020;41(7):1667-71. doi: 10.1007/s10072-020-04486-3.
Saniasiaya J, Islam MA, Abdullah B. Prevalence of olfactory dysfunction in coronavirus disease 2019 (COVID-19): a meta-analysis of 27,492 patients. Laryngoscope. 2021;131(4):865- 78. doi: 10.1002/lary.29286.
Ashrafi F, Ommi D, Zali A, Khani S, Soheili A, Arab-Ahmadi M, et al. Neurological manifestations and their correlated factors in COVID-19 patients; a cross-sectional study. Arch Acad Emerg Med. 2021;9(1):e34. doi: 10.22037/aaem. v9i1.1210.
- Abstract Viewed: 209 times
- PDF Downloaded: 159 times